Scope
The ESC essential messages for chronic coronary syndromes link estimated disease likelihood to imaging, selective invasive assessment, risk-adapted antithrombotic treatment and informed revascularisation decisions. They also emphasise microvascular and vasospastic disease when symptoms persist. This summary is limited to the official key messages and does not reconstruct omitted algorithms, doses or eligibility tables.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose a diagnostic pathway suited to the patient
- Use risk factors as well as classical clinical features to estimate the likelihood of obstructive coronary disease. When pre-test likelihood is very low, at or below 5%, consider deferring diagnostic testing. [1]
- Start investigation of suspected chronic coronary syndrome with non-invasive anatomical or functional imaging. Select the test using disease likelihood, patient factors affecting test performance, and local availability and expertise. [1]
- Prefer coronary CT angiography when the purpose is to exclude obstructive disease and identify non-obstructive disease. Prefer functional imaging when relating symptoms to ischaemia, assessing viability or guiding revascularisation decisions. [1]
- For absolute myocardial blood-flow measurement, PET is preferred; perfusion cardiac MRI is an alternative. Selective second-line imaging after an abnormal initial anatomical or functional test can improve selection for invasive angiography. [1]
Use invasive assessment when clinically indicated
- Use invasive coronary angiography for very high pre-test or post-test disease likelihood, severe symptoms despite guideline-directed treatment, angina with little exercise, or high event risk. [1]
- When angiography is indicated, assess the functional significance of intermediate stenoses with invasive testing such as FFR or iFR before deciding on revascularisation. [1]
- Use imaging guidance when undertaking complex percutaneous coronary intervention. [1]
Match antithrombotic intensity and duration to risk
- For obstructive atherosclerotic disease in chronic coronary syndrome, long-term treatment generally uses a single antiplatelet drug, aspirin or clopidogrel. [1]
- Long-term treatment with two antithrombotic agents is reasonable in patients with high thrombotic risk provided bleeding risk is not high. [1]
- For patients in sinus rhythm undergoing PCI, give dual antiplatelet treatment at the procedure and continue for 1–6 months according to bleeding risk; the source associates shorter duration with high bleeding risk. [1]
- For patients who need oral anticoagulation and undergo PCI, consider anticoagulation plus aspirin and clopidogrel for 1–4 weeks, followed by anticoagulation plus clopidogrel for up to 6 months without high ischaemic risk or up to 12 months with high ischaemic risk, then anticoagulation alone. [1]
Discuss benefits according to anatomy and ventricular function
- For functionally significant multivessel disease, explain that revascularisation can improve symptoms and reduce spontaneous infarction and cardiovascular mortality over longer follow-up compared with medical treatment alone. [1]
- Do not promise an overall survival gain from revascularisation in patients with normal ventricular function and without significant left main or proximal LAD disease. The source does not show such a survival advantage over medical treatment alone. [1]
- In patients with reduced ventricular function and ischaemic cardiomyopathy, explain that surgical revascularisation has shown an overall survival advantage over medical treatment alone at very long follow-up. [1]
- For suitable patients with complex multivessel disease without left main disease, especially those with diabetes, discuss the longer overall survival reported with bypass surgery versus PCI. Patients suitable for either approach also face a greater likelihood of repeat revascularisation after PCI. [1]
Treat symptoms, prevention and non-obstructive mechanisms
- Combine lifestyle and risk-factor changes with disease-modifying and antianginal medication. Provide similar guideline-directed preventive treatment for women and men despite differences in presentation. [1]
- Use patient-centred shared decisions to choose the treatment pathway and provide education to support sustained risk-factor control. [1]
- Recognise that symptoms of obstructive disease can overlap with microvascular dysfunction or vasospasm. Persistent symptoms despite guideline-directed therapy in suspected ANOCA or INOCA warrant invasive coronary functional testing to identify the underlying mechanism and guide therapy. [1]
Limitations and use
- This summary covers the ESC key messages on chronic coronary syndromes. Detailed diagnostic algorithms, drug doses, treatment eligibility, exceptions and evidence tables require the complete guideline.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Chronic coronary syndromes — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- ESC
- First published
- 30 August 2024
- Resource type
- Clinical practice guideline · House clinical summary
- Source setting
- Europe
Earlier House summaries: chronic coronary syndromes esc
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.